0000950170-24-027986.txt : 20240307 0000950170-24-027986.hdr.sgml : 20240307 20240307162032 ACCESSION NUMBER: 0000950170-24-027986 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240305 FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daniell Richard CENTRAL INDEX KEY: 0001726096 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 24730423 MAIL ADDRESS: STREET 1: 5 BASEL STREET, PO BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 4 1 ownership.xml 4 X0508 4 2024-03-05 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001726096 Daniell Richard C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false Exec. VP, European Commercial true Ordinary Shares 2024-03-05 4 M false 22576 A 92346 D Ordinary Shares 2024-03-05 4 S false 22576 13.5154 D 69770 D Ordinary Shares 2024-03-05 4 M false 55226 A 124996 D Ordinary Shares 2024-03-05 4 S false 26053 13.5154 D 98943 D Restricted Share Units 2024-03-05 4 M false 22576 0 D Ordinary Shares 22576 22576 D Restricted Share Units 2024-03-05 4 M false 55226 0 D Ordinary Shares 55226 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 2024-03-07